Evaluation of Optimal Combination of Commercially Available Superparamagnetic Iron Oxide Nanoparticles and Transfection Agents for Labelling of Human Mesenchymal Stem Cells.
10.13104/jksmrm.2012.16.1.31
- Author:
Sung Hun KIM
1
;
Soon Nam OH
;
Youn Hee PARK
;
Won Kyung KANG
;
Kook Jin AHN
;
Soo Kyo CHUNG
Author Information
1. Department of Radiology, College of Medicine, The Catholic University of Korea, Korea. ahn-kj@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Cell labeling;
Contrast media;
Experimental studies;
Iron;
Magnetic resonance (MR)
- MeSH:
Cell Survival;
Contrast Media;
Dextrans;
Ferric Compounds;
Humans;
Iron;
Magnetite Nanoparticles;
Mesenchymal Stromal Cells;
Nanoparticles;
Protamines;
Stem Cells;
Transfection
- From:Journal of the Korean Society of Magnetic Resonance in Medicine
2012;16(1):31-39
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To determine the optimal combination of commercially available superparamagnetic iron oxide (SPIO) nanoparticles with transfection agents (TA). MATERIALS AND METHODS: Protamine sulfate (Pro) and poly-L-lysin (PLL) were incubated with ferumoxide and ferucarbotran in human mesenchymal stem cells at various concentrations, and cellular viability were evaluated. Cellular iron uptake was qualitatively and quantitatively evaluated. Cell visibility was assessed via MR imaging and the T2-relaxation time was calculated. RESULTS: The cellular viabilities with ferucarbotran were more significantly decreased than those with ferumoxide (p < 0.05). Iron uptake with ferumoxide was significantly higher than that for those with with ferucarbotran. The T2-relaxation time was observed to be shorter with ferumoxide in comparison to those with ferucarbotran (p < 0.05). Ferumoxide at a concentration of 25 microg/ml in combination with either Pro or PLL at a concentration of 3.0 microg/ml did not adversely impact cell viability, maximized iron uptake, and exhibited a lower T2-relaxation time in comparison to other combinations. CONCLUSION: Stem cells with ferumoxide exhibited a higher cellular viability and iron uptake in comparison to ferucarbotran- treated stem cells. A 25 microg/ml of ferumoxide with a 3.0 microg/ml of TA is sufficient to label mesenchymal stem cells.
